Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4565 On Other Exchanges
4565 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sosei group corp (4565) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOSEI GROUP CORP (4565)

Related News

No related news articles were found.

sosei group corp (4565) Related Businessweek News

No Related Businessweek News Found

sosei group corp (4565) Details

Sosei Group Corporation, a biopharmaceutical company, develops and commercializes pharmaceutical drugs worldwide. It offers NorLevo, an oral emergency contraceptive pill. The company’s product pipeline includes Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD), as well as conducts a Phase III clinical trial program for uncontrolled asthma; and Ultibro/QVA149, an inhalation capsules for the maintenance bronchodilator treatment of COPD. Its product pipeline also comprises SO-1105, an antifungal agent for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are ophthalmic solutions in pre-clinical stage for infectious cornea inflammation, infectious conjunctivitis, etc. Sosei Group Corporation was incorporated in 1990 and is headquartered in Tokyo, Japan.

30 Employees
Last Reported Date: 06/25/14
Founded in 1990

sosei group corp (4565) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sosei group corp (4565) Key Developments

Sosei Group Corporation, Heptares Therapeutics Ltd. - M&A Call

Sosei Group Corporation, Heptares Therapeutics Ltd. - M&A Call

Sosei Group Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Year Ending March 31, 2015

Sosei Group Corporation reported consolidated earnings results for the nine months ended December 31, 2014. For the period, the company reported revenue in this quarter totaled JPY 951 million against JPY 1,838 million a year ago, as a result of received royalties from Seebri (NVA237) and Ultibro (QVA149). A 48.2% decrease of revenue compared to the same period of the previous financial year was due to the milestone payments for Seebri and Ultibro that were received in the same period of the previous year, and were not expected in this quarter. The Group recorded operating income of JPY 16 million. A decrease of JPY 920 million from the comparative period of the previous financial year is primarily due to decrease in revenue. The Group recorded net income of JPY 262 million. A decrease of net income of JPY 702 million from the comparative period of the previous financial year is primarily due to decrease in revenue. Cash flows from operating activities in this quarter amounted to JPY 343.927 million against JPY 614.988 million a year ago, mainly due to having received advance payments of JPY 300 million. Purchases of property, plant and equipment was JPY 12.471 million against JPY 9.922 million a year ago. Net income before income taxes was JPY 383.525 million against JPY 967.485 million a year ago. Net income per diluted share was JPY 18.87 against JPY 79.62 a year ago. For the year ending March 31, 2015, the company expects revenue of JPY 3,300 million, operating income of JPY 2,000 million, net income before income taxes of JPY 2,000 million, net income attributable to owners of the parent company of JPY 2,000 million or JPY 145.46 per share.

Sosei Group Corporation to Report Q3, 2015 Results on Feb 12, 2015

Sosei Group Corporation announced that they will report Q3, 2015 results on Feb 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4565:JP ¥3,445.00 JPY +150.00

4565 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4565.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4565 Industry Range
Price/Earnings 21.6x
Price/Sales 40.8x
Price/Book 3.2x
Price/Cash Flow 47.6x
TEV/Sales 34.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOSEI GROUP CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at